Kintara Therapeutics (NASDAQ:KTRA) Now Covered by Maxim Group

Investment analysts at Maxim Group initiated coverage on shares of Kintara Therapeutics (NASDAQ:KTRA) in a research report issued to clients and investors on Friday, TipRanks reports. The brokerage set a “buy” rating and a $3.00 price target on the stock. Maxim Group’s price objective would suggest a potential upside of 106.90% from the company’s current price.

Separately, Aegis restated a “buy” rating and set a $6.00 price objective on shares of Kintara Therapeutics in a report on Thursday, October 1st.

KTRA stock opened at $1.45 on Friday. The business’s 50-day simple moving average is $1.48. The company has a market capitalization of $35.76 million, a price-to-earnings ratio of -1.65 and a beta of 1.82. Kintara Therapeutics has a 1-year low of $0.38 and a 1-year high of $1.95.

Kintara Therapeutics (NASDAQ:KTRA) last released its quarterly earnings results on Monday, September 21st. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.16). As a group, equities analysts forecast that Kintara Therapeutics will post -0.34 earnings per share for the current year.

A hedge fund recently bought a new stake in Kintara Therapeutics stock. IPG Investment Advisors LLC purchased a new stake in Kintara Therapeutics, Inc. (NASDAQ:KTRA) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 26,000 shares of the company’s stock, valued at approximately $36,000. IPG Investment Advisors LLC owned 0.11% of Kintara Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 2.14% of the company’s stock.

About Kintara Therapeutics

Kintara Therapeutics, Inc, a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer.

Further Reading: How is an ETF different from a mutual fund?

Receive News & Ratings for Kintara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kintara Therapeutics and related companies with's FREE daily email newsletter.